Drug Profile
Research programme: oral anticancer drugs - Athenex
Alternative Names: oral anticancer drugs + apigenin flavonoid dimer - AthenexLatest Information Update: 17 Apr 2024
Price :
$50
*
At a glance
- Originator Kinex Pharmaceuticals
- Developer Hong Kong Polytechnic University; McGill University
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer